InMode Ltd. Ordinary Shares (INMD) Stock Price
INMDStock
$14.16−6.96%52W
Market Cap$814.83M
P/E8.68x
PEG Ratio0.83
Div yield—
Beta1.99
INMD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-9.76%
Price vs S&P 500 (4W)-1.02%
PEG Ratio0.83
VGM Score57.96
P/E Ratio (Annual)8.68x
INMD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.33 | $0.35 | +5.42%(+$0.02) | |
| Q1 2026 | $0.30 | $0.25 | -16.06%(-$0.05) | |
| Q4 2025 | $0.42 | $0.46 | +10.39%(+$0.04) | |
| Q3 2025 | $0.35 | $0.38 | +7.05%(+$0.03) | |
| Q2 2025 | $0.41 | $0.47 | +14.54%(+$0.06) |
INMD Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.75
3.75
3.75
3.75
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
INMDInMode Ltd. Ordinary Shares | A | D | C | 2.2x | 12.4% | 76.5% | 18.5% | $14.16 |
| MDTMedtronic plc | B | C | B | 3.2x | 3.8% | 65.7% | 18.1% | $94.75 |
| ITGRInteger Holdings Corporation | C | C | A | 2.3x | 11.6% | 26.1% | 9.7% | $126.70 |
| LIVNLivaNova PLC Ordinary Shares | C | B | B | 2.9x | 8.2% | 68.1% | 12.5% | $77.58 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | 3.7x | 88.2% | 58.7% | 12.2% | $70.78 |
| AXGNAxogen, Inc. Common Stock | F | B | B | 8.1x | 14.9% | 74.6% | -11.8% | $34.62 |
| BLFSBioLife Solutions Inc. | F | C | A | 18.4x | 14.9% | 63.9% | 2.9% | $38.61 |
| CNMDCONMED Corporation | B | C | B | 1.0x | 9.8% | 55.8% | 8.0% | $46.72 |
| CBLLCeriBell, Inc. Common Stock | F | A | A | 9.4x | — | 88.9% | -68.6% | $25.04 |
| CVCapsoVision, Inc. Common Stock | F | D | B | 25.0x | — | 50.9% | -217.1% | $6.53 |
| ELMDElectromed, Inc. | C | B | C | 3.1x | 15.6% | 78.5% | 18.8% | $27.42 |
About InMode Ltd. Ordinary Shares
InMode is a provider of energy-based treatment platforms for minimally invasive aesthetic and medical procedures. Its technology addresses facial and body contouring, medical aesthetics, and women's health across dermatology, plastic surgery, gynecology, and ophthalmology. The company generates substantially all revenue from the United States, with growing international sales in Europe and Asia.